Contract Services

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

 Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort -  Results indicate CD73 expression corr...

 May 27, 2022 | News

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

10 billion KRW invested in Hanmi Fine Chemical facility expansion  Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutic...

 May 23, 2022 | News

Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award

Company efforts balance strategic growth and sustainability A successful record of meeting increasing market dynamics Ongoing commitment to fulfilling ...

 May 19, 2022 | News

Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:- Dr. Raman...

 May 12, 2022 | News

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of ...

 May 11, 2022 | News

Novotech Acquires US CRO NCGS, Expands Global Expertise

Novotech CEO Dr. John Moller said "We are very pleased to acquire such an impressive company with a strong history of quality and delivery in the United St...

 May 05, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

 May 02, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

    IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

 April 28, 2022 | News

WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability

One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enabling nearly 30 Investigational New Drug Applications (...

 April 28, 2022 | News

Samsung Biologics completes full acquisition of Samsung Bioepis

Samsung Biologics (KRX: 207940.KS) announced today that it has completed the purchase of Biogen's stake in the Samsung Bioepis joint venture for USD $...

 April 21, 2022 | News

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S

MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the ...

 April 20, 2022 | News

WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

This marks the second consecutive year that WuXi Bio has received this award from IMAPAC, a leading consulting firm in biopharmaceutical industry.  S...

 April 18, 2022 | News

Merck Advances BioProcessing Capabilities with Acquisition of MAST® Platform from Lonza

Merck to become first company to offer a fully integrated ecosystem for advanced process technologies Brings biopharmaceutical industry closer to digita...

 April 14, 2022 | News

CDMO's Shifting Focus to Meet Future Demand

Transformational forces are influencing the global contract development and manufacturing organization (CDMO) market's growth. Disruptive, innovative busin...

 April 08, 2022 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in